BioAtla
BCAB
86 hedge funds and large institutions have $746M invested in BioAtla in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 12 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
13% more funds holding
Funds holding: 76 → 86 (+10)
0.25% more ownership
Funds ownership: 1.32% → 1.57% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $897M → $746M (-$150M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.6M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$32.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$28.3M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$13.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$28.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$10.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.48M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.3M |
BCAB Hedge Fund Activity: Q3 2021 in Review
86 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q3 2021, worth a combined $746M — down 17% from $897M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new BCAB positions and 12 closed out — a net gain of 10 holders — while 37 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $40.6M. The largest seller was Farallon Capital Management, cutting an estimated $28.1M.
- 86 institutional investors held BioAtla (BCAB) as of Q3 2021, up from 76 in Q2 2021.
- Funds reported $746M of BioAtla stock for Q3 2021, down 17% quarter-over-quarter.
- 22 funds opened new BioAtla positions in Q3 2021 and 12 closed out, a net change of +10 holders.
- The largest BioAtla buyer in Q3 2021 was Vanguard Group, an estimated $40.6M added.
- The largest BioAtla seller in Q3 2021 was Farallon Capital Management, an estimated $28.1M sold.
Based on aggregated 13F filings for Q3 2021.